- Home
- INO
as 07-29-2025 12:38pm EST
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | PLYMOUTH MEETING |
| Market Cap: | 69.3M | IPO Year: | 1998 |
| Target Price: | $8.80 | AVG Volume (30 days): | 3.3M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $11.44 | Next Earning Date: | 08-07-2025 |
| Revenue: | $283,099 | Revenue Growth: | -60.52% |
| Revenue Growth (this year): | -63.36% | Revenue Growth (next year): | 20588.06% |
Latest Inovio Pharmaceuticals Inc. News
INO Breaking Stock News: Dive into INO Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Inovio Pharmaceuticals (NASDAQ:INO) Will Have To Spend Its Cash Wisely
Thomson Reuters StreetEvents
3 months ago
Q1 2025 Inovio Pharmaceuticals Inc Earnings Call
MT Newswires
3 months ago
Oppenheimer Adjusts Inovio Pharmaceuticals Price Target to $13 From $15, Maintains Outperform Rating
GuruFocus.com
3 months ago
Inovio Pharmaceuticals Inc (INO) Q1 2025 Earnings Call Highlights: Strategic Cost Management ...
Zacks
3 months ago
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
Associated Press Finance
3 months ago
Inovio: Q1 Earnings Snapshot
PR Newswire
3 months ago
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights
PR Newswire
3 months ago
INOVIO to Present at Upcoming Scientific and Investor Conferences
Compare INO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INO Inovio Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.